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Health economics, as an interdisciplinary science, has experienced exceptionally bold 
evolution through the past eight decades. Generations of committed scholars have 
built up huge body of knowledge and developed a set of methodological tools to assist 
health-care authorities with resource allocation process. Following its conception at the 
US National Bureau of Economic Research and Ivy League US Universities, this science 
has spread across the Globe. It has adapted to a myriad of local conditions and needs 
of the national health systems with diverse historical legacies, medical services provi-
sion, and financing patterns. Challenge of financial sustainability facing modern day 
health systems remains primarily attributable to population aging, prosperity diseases, 
large scale migrations, rapid urbanization, and technological innovation in medicine. 
Despite promising developments in developing countries with emerging BRICS markets 
on the lead, rising out-of-pocket health spending continues to threaten affordability of 
medical care. Universal health coverage extension will likely remain serious challenge 
even for some of the most advanced OECD nations. These complex circumstances 
create strong drivers for inevitable further development of health economics. We believe 
that this interdisciplinary health science shall leave long-lasting blue print to be visible 
for decades to come.
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hiStOrical rOOtS OF health ecOnOMicS
Health economics is the leading interdisciplinary science that bridges the gap between the theory 
of economics and practice of health care. It has experienced great development with earliest roots 
dating back for almost entire century. Its extensive diversification into various subdisciplines and 
areas of research endeavor is clearly visible today. Thus, it makes an uneasy task to track for its shy 
historical roots and preconditions for the birth of this science. Few would argue that actual cradle of 
this knowledge was academic tradition of the U.S.
Influential impact of the American institutions founded during the heights of Cold War rivalry 
extended far beyond their initially supposed outreach. One of the milestone events in the U.S. was 
establishment of Bureau of Medical Economics by American Medical Association (AMA) back in 
1931. Shortly after the end of WWII, in 1945, the U.S. Army established the so-called RAND Project 
that grew in consecutive years to become RAND Corporation. Initially, its take was to apply math-
ematical Game Theory allowing for predictions of plausible scenarios in the geopolitical competition 
with the USSR. Many years after, applications of this same “rational choice” theoretical framework 
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has found its civilian applications in areas such as the build-up 
of welfare state in liberal capitalism, social affairs, and ultimately 
economics of health care (1).
Some of the first pioneering works prior to WWII can be 
found in publications by Milton Friedman back in the 1930s 
(2, 3). Most commonly cited source responsible for name “bap-
tism” of this science is Selma Muskin’s paper published 1958 
entitled: “Towards the definition of health economics” (4) to be 
followed by her another famous paper “Health as an Investment” 
in 1962 (5). At that time, health was broadly regarded as rather 
consumptive branch of the economy. Mushkin’s analysis was 
probably the first understanding that health investment has 
long-term beneficial consequences for the community. Probably, 
single most famous and cited contribution laying grounds for 
this discipline was Kenneth Arrow’s paper “Uncertainty and the 
welfare economics of medical care” published in 1963 (6). These 
arguments were further extended by Michael Grossman who 
became known worldwide for authoring the Theory of Human 
Capital in 1972 (7). Interestingly, this method to assess indirect 
opportunity costs of lost productivity became standard in health 
economics. It continued to attract academic attention for many 
decades, and its creator even published two anniversary papers in 
recent years (8, 9). This same year was remembered for one more 
classical piece by Victor Fuchs entitled: Who Shall Live? (10). This 
contribution probably puts grounds for ethical consideration in 
health economics that are about to remain hot topics until today.
Particularly useful insight was provided by recent bibliographic 
study based on EconLit and Google Scholar indexing databases 
encompassing 40 years of health economics development from 
1971 to 2011 published by Wagstaff and Culyer (11). It gives 
us thorough evidence on regional distribution of most relevant 
publications, top ranked academic institutions, and top cited 
researchers. Although discipline evidently accelerates since the 
1960s, there is clear gap in favor of the U.S., which hosts almost 
70% of top 100 researchers. It was distantly followed by Canada, 
UK, Australia, and afterward few continental European countries 
such as the Netherlands and Sweden. Top five most influential 
journals listed were Journal of Health Economics, Health 
Economics, Health Services Research, Pharmacoeconomics, and 
Journal of Human Resources. Top 10 most cited scientists globally 
according to multiple criteria (h-index, I3 factor, cumulative cita-
tion rate, etc.) were (in decreasing order of appearance) David M. 
Cutler, Jonathan Gruber, Paul Newhouse, Mark V. Pauly, W. Kip 
Viscusi, Janet M. Currie, Michael Grossman, Frank A. Sloan, 
Adam Wagstaff, and Eddy van Doorslaer. According to their 
h-index, the highest ranked institutions were Harvard University, 
World Bank, MIT, University of California at Berkeley, Chicago 
University, Pennsylvania University, Michigan University, and 
York University being the only European higher education estab-
lishment among the top ten.
Beginning from its very inception in the U.S. in between the 
1940s and 1960s, health economics productivity continues to 
outpace European and that of major Asian economies, led by 
Japan (12). While the U.S. dominance in the output measures 
of health economics is still apparent, its monopoly is weaken-
ing for technical and substantive reasons. Technically, the high 
quality micro-data on individuals and households, essential for 
health economics that had been available only in the U.S., are 
now available in Europe and East Asian countries. Furthermore, 
even the latest quantitative tools in health economics find their 
way into these countries in no time through electronic journals 
and textbooks. However, most compelling reasons come from the 
huge differences between U.S. and the other countries, including 
Western Europe and Japan. U.S. is not a typical high-income 
country in the world; it has been almost the only country without 
universal coverage among OECD countries, many of its public 
health issues are unique, whose individualistic behaviors and 
values are often not shared by other countries. Countries with 
universal health insurance coverage often faced financial crisis 
much earlier due to population aging, and countries that followed 
simplistic text-book policy prescriptions often failed (13).
We should be aware that aforementioned bibliographic 
evidence published by World Bank, regardless of its undisputed 
methodological soundness, is some 5 years outdated. Since the 
late 1980s and the end of Cold War Era, health economics rapidly 
expanded worldwide (14). Leading engines of such development 
were academic centers of excellence whose establishment began 
in Western Europe (15) and Japan as early as in the 1970s (16). 
Furthermore, the process of mushrooming of scientific endeavor, 
funded research, establishment of under- and postgraduate cur-
ricula, and publication of textbook materials (17) in major world 
languages accelerated (18). Following traditional OECD econo-
mies (19, 20), new cores of fruitful efforts in the field occurred in 
major emerging markets such as the BRICS (21, 22) nations and 
Eastern Europe (22). Some of the prominent examples of such 
countries hosting some of the top 25 ranked centers of excellence 
were Taiwan (China), South Africa, China, and India (23). On the 
opposite side, clearly recognized geographical areas presenting 
almost serious lack of health economist capacities and locally 
published knowledge are most of the sub-Saharan Africa and 
Middle Eastern and Central Asian regions (24).
Large part of preconditions for such an extensive evolution 
were legislative changes across the Globe driven by the increasing 
costs of medical cares, slowing-down in economic growth, and 
the intensifying competition for the limited resources among the 
sectors of health care. Since the early 1990s, many governments, 
led by Australian (25) and Canadian (26) examples, adopted 
budget-impact and cost-effectiveness evidence as mandatory 
for new medical technologies approval and reimbursement. This 
wise decision effectively improved resource allocation strategies 
across the world, leading to better access and affordability of 
medical services to the general population (27). On the other 
side, it created an administrative pressure toward the manu-
facturers of pharmaceuticals and medical equipment. These, in 
turn, led to a great diversity of new job openings for professional 
industry-affiliated health economists (28). All these intercon-
nected developments in the triangle of the national authorities, 
academia, and industry led to a great increase of capacities in 
terms of both knowledge and its applications.
Methodological mile stone essential to cost-effectiveness 
equation was reliable assessment of clinical efficiency of certain 
medical technology (29). Important step in this direction was 
revealing concept of evidence-based medicine (EBM) (30). It 
was applied straightforward in the UK via regular publication of 
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Cochrane Systematic Reviews (31) and work of National Institute 
for Health and Care Excellence (NICE) (32). One step further in 
the same direction was development of health technology assess-
ment (HTA) procedures (33). Establishment of national HTA 
agencies across the world throughout INAHTA-coordinated (34) 
efforts served as one of the long-term foundation stones, support-
ing the core place of health economics in health policy.
the chanGinG WOrld – neW 
challenGeS FOr the GlOBal health
Post WWII global development was characterized by several core 
landmarks of geopolitical evolution. Early decades were marked 
by demographic explosion, end of Colonial Era, 45 years of Cold 
War rivalry between the U.S. and USSR, rise of the Non-Aligned 
Movement (35), industrial revolution spreading from developed 
toward Third World economies (36), large scale migrations (37), 
environmental pollution (38), and ultimately global warming 
effect (39). Such a complex and dynamic socioeconomic evolu-
tion, both in free market capitalist and former socialist economies 
with some lag, led to technological advances and improved health 
outcomes with longevity on the lead (40). These major develop-
ments have accelerated hierarchical establishment and spreading 
of large national health systems across the world. The very idea of 
risk sharing and conception of early health insurance funds dates 
back to the nineteenth century Europe (41). After the WWII, 
the bulk of medical innovation moved from Europe to the U.S. 
Peculiarity is the fact that the first nation to effectively deliver 
universal health coverage for almost entire population including 
the poor, back in the 1930s, was USSR via its renowned Semashko 
system. Other countries adopted different strategies to provide 
universal health coverage – ranging from systems based on the 
state budget, through public insurance systems, to more market-
oriented solutions with Bismarckian, Beveridge, and U.S. system 
being the most prominent examples. Great attainments in living 
standards, education, medical care, and public health policy led to 
bold advances in population health indicators. These were most 
visible in the U.S., Western European nations, and Japan at the 
time. They consisted of extended longevity, falling fertility rates, 
decreasing morbidity from infectious diseases, improved mater-
nal health, and early childhood survival. With some gap, they 
were followed by the socialist countries. Low-income Southern 
Hemisphere nations of Africa, Latin America, and Asia remained 
significantly below these thresholds and needed decades to catch 
pace with the industrialized economies of the North (42).
Since the end of Cold War Era, observing the time horizon 
1989–2016 World has become a much different place. During 
the 1990s and early 2000s, globalization processes continued to 
accelerate worldwide. This meant rise of the newly industrialized 
or the so-called “emerging” markets such as the BRICS (43) and 
Next Eleven nations (44), heavily dominated by the overachieve-
ment of People’s Republic of China (45). In health-care arena, 
it has reflected in so called transitional health-care reforms 
with the most typical pattern in Eastern Europe. These reforms 
tended to move focus of former socialist health systems from 
curative, hospital-based health care toward preventive-oriented, 
outpatient-centered health care. Health financing pattern tended 
to make relief to state-owned health insurance funds toward 
ever larger share of the out-of-pocket spending by the ordinary 
citizens (46).
Population aging as a global phenomenon (47, 48) became 
evident over the past three decades, with Japan on the lead (49, 
50). Current UN forecasts indicate that China will be fastest aging 
large nation deep into the twenty-first century (51). Surprisingly, 
aging of nations ultimately reached some of the traditionally 
young nations such as the Arabic (52) ones of MENA region and 
Turkey (53). Such a huge demographic transition was virtually 
unpredictable for strategic thinkers of nineteenth century. Soon, 
it became obvious that this population change will be coupled 
with explosive increase in incidence and prevalence of non-
communicable “prosperity diseases” (NCDs). Remarkable fea-
ture of core NCDs is their chronical clinical course characterized 
with growth in medical services demand, long lasting disability, 
work absenteeism, and premature mortality. The third major con-
tributor to the skyrocketing costs of medical care provision was 
technological innovation in medicine. Diagnostic frontiers and 
therapeutic opportunities extended tremendously. Availability 
of cutting-edge technologies joined with improved affordability 
of ordinary “golden-standard” services leads to increased citizen 
demand, further threatening financial sustainability of con-
temporary systems. Cost containment efforts and polices soon 
became top policy priority not only in rich Western and Asian 
countries but elsewhere across the globe as well.
health ecOnOMicS – cOntriBUtiOn 
tO MOdern day health SySteMS
It is broadly recognized that building of health care capacities has 
high, but long-term, return on investment in terms of popula-
tion health and an overall societal productivity. Throughout 
the past half a century and more, the great legacy of academic 
health economics has created huge diversity of methodological 
tools to assist resource allocation processes. Some of the most 
commonly used were cost-effectiveness, cost-utility, cost-benefit, 
budget-impact, and resource utilization analysis. It continues to 
strive and create new approaches for the future such as improving 
management of scarce resources through managed and integrated 
care environment.
Health economics has established itself as a mature science 
long time ago. The landscape of its major subdisciplines remained 
essentially unchanged since the 1970s, although some areas were 
getting momentum more rapidly than others. This happened due 
to a myriad of local circumstances in the largest, most advanced 
health markets notably in Northern America, Western Europe, 
Far East of Asia, and Australia. To some extent, this focus of 
academic interest was driven by legislative framework and 
priorities of major research funding agencies (54–57). Another 
factor was pharmaceutical and medicinal device industry motive 
to invest heavily into those branches of health economics they 
regarded essential for the success of their market access and 
reimbursement strategies (58, 59). Last but not least, academia 
itself recognized the core weaknesses of national health systems 
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and adapted responding to local needs (60). Thus, the major 
fields of scientific endeavor in health economics and its fruits 
were different in the U.S., Benelux, and Nordic regions of Europe 
and Japan. According to Wagstaff and Culyer based on EconLit-
adopted JEL system, over the past 40 years, these disciplines were 
health and its value, efficiency and equity, determinants of health 
and ill-health, public health, health and the economy, health 
statistics and econometrics, demand for health and health care, 
health insurance, supply of health services, human resources, and 
markets in health care and economic evaluation.
Great legacy of academic health economics shall remain one 
of the prime examples of bold development of interdisciplinary 
health sciences. It has served governments, hospital sectors, and 
pharmaceutical and medicinal device industry across the world 
for more than half a century. This knowledge has facilitated wiser 
and more just resource allocation. It allowed to the national 
health systems worldwide to deliver more medical care, save more 
lives, extend human longevity, and improve the quality of life in 
patients suffering from chronic illness probably as much as core 
medical discoveries themselves. This contribution is less obvious 
compared to the innovation in clinical medicine. But far-reaching 
consequences of implementing methods of health economics in 
policy decisions have made medical services far more affordable 
and accessible to ordinary people than ever before (61, 62). Thus, 
a scientific discipline, originally stemming from the Game 
Theory, gave birth to several generations of gifted and devoted 
economists, physicians, and other expert profiles. All of them 
were building huge body of knowledge that continues to grow 
further. We witness complex evolution of global population health 
landscape across nations. Such a profound and long-term change 
creates a major challenge of financial sustainability of modern day 
health systems. Contemporary health policy elites believe that 
achievement of universal health coverage remains primary goal 
(63). We believe that these circumstances create strong long-term 
drivers for inevitable further development of the science of health 
economics. For many years, it has been supporting the build up of 
welfare societies in many nations (64). Whether health economics 
shall remain in the elite club of interdisciplinary health sciences 
exhibiting long-lasting impact to policy-making and strategic 
thinking will be seen in the upcoming decades.
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